| Qian, Wenbin |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
NCT06508983: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 360 | RoW | SG301 Injection, SG301 placebo, pomalidomide, dexamethasone | Hangzhou Sumgen Biotech Co., Ltd. | Relapsed/Refractory Multiple Myeloma | 03/27 | 03/28 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
NCT04706936: Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma |
|
|
| Recruiting | 1 | 25 | RoW | anti-BCMA CAR-T, CBG-002 CAR-T, Cyclophosphamid, Fludarabine | Second Affiliated Hospital, School of Medicine, Zhejiang University, Carbiogene Therapeutics Co. Ltd. | Relapsed or Refractory Multiple Myeloma | 10/23 | 04/24 | | |
NCT04795128: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy |
|
|
| Completed | 1 | 70 | RoW | IBI322 | Innovent Biologics (Suzhou) Co. Ltd. | Hematologic Malignancy | 08/23 | 08/23 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
